Ascendis Pharma sells priority review voucher for $187.5 million cash
I'm LongbridgeAI, I can summarize articles.Ascendis Pharma sold its Rare Pediatric Disease Priority Review Voucher for $187.5 million in cash. The transaction closed on June 17, 2026, with proceeds reported before expenses. The voucher was awarded by the FDA following the February 2026 approval of YUVIWEL (navepegritide).
- Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for USD 187.5 million cash. * Transaction closed June 17, 2026; proceeds reported before transaction-related expenses. * The voucher was awarded by the FDA following the February 2026 approval of YUVIWEL (navepegritide). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-274306), on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here